Onkourologiya最新文献

{"title":"Luteinizing hormone-releasing hormone agonists for prostate cancer patients: routine clinical practice of Russian cancer urologists","authors":"V. Matveev, B. Alekseev, B. Kamolov, A. Markova","doi":"10.17650/1726-9776-2021-17-2-83-92","DOIUrl":"https://doi.org/10.17650/1726-9776-2021-17-2-83-92","url":null,"abstract":"Background. Despite the recent amendments to the guidelines for the treatment of metastatic hormone-sensitive prostate cancer (PCa) implying standard use of luteinizing hormone-releasing hormone (LHRH) agonists in combination with chemotherapy or androgen inhibitors, androgen deprivation therapy (ADT) remains an essential component of treatment for advanced PCa. Testosterone target castration level of 20 ng/dL implies routine measurement of testosterone levels along with prostate-specific antigen (PSA) levels during ADT. It is particularly interesting to evaluate the frequency of achieving castration testosterone level in routine clinical practice. Objective: to assess the frequency of achieving castration testosterone level (20 ng/dL) and maintaining it after 6 months of therapy in patients with hormone-sensitive PCa receiving an LHRH agonist for the first time. Materials and methods. In 2019-2020, Russian Society of Cancer Urologists conducted a non-interventional prospective multicenter study (observational program) aimed to evaluate the efficacy of LHRH agonist (including buserelin, goserelin, leuprorelin or triptorelin) in routine clinical practice in Russia. This study involved 39 cancer urologists and 479 patients aged 18 years and older diagnosed with hormone-sensitive PCa, who started their ADT with LHRH agonists for the first time regardless of the disease stage and previous treatment. Patients received hormone therapy with an LHRH agonist for at least 6 months, visiting their doctor every 3 months (visit 1; visit 2: after 3 months; visit 3: after 6 months). Results. Patients received one of the following drugs: leuprorelin (3.75 mg; 7.5 mg; 22.5 mg; 45 mg; n = 225; 47,0 %), goserelin (3.6 mg; 10.8 mg; n = 132; 27.5 %), buserelin (3.75 mg; n = 67; 14.0 %), and triptorelin (3.75 mg; 11.25 mg; n = 55; 11.5 %). Of 479 patients, 186 (38.8 %) received combination treatment with bicalutamide, 12 (2.5 %) with fluta-mide, 54 (11.3 %) with zoledronic acid, and 11 (2.3 %) with denosumab. Among 146 patients with metastatic PCa, a combination of ADT plus docetaxel was administered to 30 participants (20.6 %), ADT plus abiraterone to 8 participants (5.5 %), and ADT plus enzalutamide to 2 participants (1.4 %). After 6 months of therapy, mean PSA level decreased by 94.2 % (from baseline 118.12 ng/mL to 6.87 ng/mL). Mean testosterone level was 19.0 ng/dL (range: 0.029-100 ng/dL). Among 430 patients, the targeted testosterone level <20 ng/dL was achieved in 257 individuals (59.8 %); the level of 20-50 ng/dL was achieved in 158 individuals (36.7 %); and fifteen patients (3.5 %) had their testosterone level >50 ng/dL. The incidence of adverse events was low; most of them were mild. Conclusion. Our findings suggest that not all patients achieve targeted testosterone level of <20 ng/dL, which corroborates the need for routine monitoring of testosterone levels during therapy to ensure its timely correction. We observed frequent administration of ADT with max","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"43 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67766603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of the article “Comparison of clips and electrosurgical instruments in sealing of lymphatic vessels during pelvic lymph node dissection at the time of radical cystectomy”","authors":"К. М. Нюшко","doi":"10.17650/1726-9776-2021-17-2-103","DOIUrl":"https://doi.org/10.17650/1726-9776-2021-17-2-103","url":null,"abstract":"Рак мочевого пузыря (РМП) является актуальной проблемой современной онкоурологии и занимает одно из лидирующих мест в структуре онкоурологической патологии. Хирургическое лечение является золотым стандартом при проведении радикального лечения у больных данной патологией. У больных мышечно-инвазивным РМП радикальная цистэктомия, подразумевающая удаление мочевого пузыря в едином блоке с предстательной железой и семенными пузырьками у мужчин или одномоментной экстирпацией матки с придатками и резекцией передней стенки влагалища у женщин в сочетании с одномоментным выполнением расширенной тазовой лимфаденэктомии до уровня бифуркации аорты или до нижней брыжеечной артерии (в случае наличия визуально измененных лимфатических узлов в полости малого таза) является общепризнанным стандартом. Такой существенный объем хирургического вмешательства зачастую может приводить к развитию серьезных осложнений и нежелательных побочных эффектов операции, а расширенная лимфаденэктомия зачастую может сопровождаться явлениями длительной лимфореи, образованием симптоматических лимфокист, требующих дренирования после операции, а также явлениями лимфедемы (лимфостаза). По этой причине тема, предложенная авторами к рассмотрению в данной статье, является весьма актуальной. Авторы провели анализ собственных результатов лечения 60 больных, перенесших радикальную цистэктомию с различными вариантами деривации мочи и оценили риск развития осложнений, связанных с выполнением расширенной тазовой лимфаденэктомии.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67765155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The first experience of transperineal prostate biopsy without antibiotic prophylaxis","authors":"D. Chernysheva, S. Popov, I. Orlov, A. V. Tsoy, V. A. Neradovskiy","doi":"10.17650/17269776-2021-17-2-46-52","DOIUrl":"https://doi.org/10.17650/17269776-2021-17-2-46-52","url":null,"abstract":"Objective: to study the safety of omitting the antibiotic prophylaxis before transperineal prostate biopsy.Materials and methods. The prospective randomized study included data, obtained during the diagnostical process of 85 patients, who underwent transperineal prostate biopsy in 2020. In the control group (n = 50) patients received 1 g Ceftriaxone IV 1 h before the biopsy. In the study group (n = 35) biopsy was performed without previous antibacterial prophylaxis. Age median was 63.2 (52-75) years.Results. No significant differences in the infection complications rate (UTI, soft tissues infections, prostatitis, fever, sepsis) were obtained between the groups. No patient developed UTI, prostatitis or sepsis, confirmed with urine culture.Conclusion. Performing transperineal prostate biopsy without antibiotic prophylaxis seems to be a safe alternative to common prophylaxis regiments, dedicated to infection complications prevention after prostate biopsy.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67766041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of the in silico approach in the study of critical genes predicting chemotherapeutic response to oxaliplatin in treatment of prostate cancer (literature reviev)","authors":"M. V. Loginova, V. Pavlov, I. Gilyazova","doi":"10.17650/1726-9776-2021-17-2-139-144","DOIUrl":"https://doi.org/10.17650/1726-9776-2021-17-2-139-144","url":null,"abstract":"Prostate cancer is the leading cause of death among men. Existing prognostic factors make it possible to differentiate the degree of malignancy of tumors with high metastatic potential. Currently, the treatment of high-grade tumors is carried out with hormonal therapy, to which taxanes are added, when the malignant neoplasm becomes resistant to castration. Studies with other anti-cancer agents did not take into account the genetic background of the tumors, and most of the trials showed low response rates. The article describes an in silico approach for screening drug candidates that can be used as an alternative to taxanes. Researched 86 genes that distinguish between high and low grade tumors, and identified several genes that correlated with chemosensitivity. As an example, a set of six genes has been proposed the expression levels of which can predict cell sensitivity to oxaliplatin. The study demonstrates the relevance of an approach to the treatment of high-grade prostate cancer and new biomarkers for predicting clinical tumor response.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67766049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of treatment results for patients with high-risk prostate cancer according to the EAU and NCCN criteria","authors":"S. Reva, A. Nosov, V. Korol, A. Arnautov, I. Zyatchin, M. Berkut, S. Petrov, A. Belyaev","doi":"10.17650/1726-9776-2021-17-2-54-61","DOIUrl":"https://doi.org/10.17650/1726-9776-2021-17-2-54-61","url":null,"abstract":"Background. High-risk prostate cancer (PCa) occurs in 15-25 % of newly diagnosed cases and is a life-threatening condition that requires active treatment. In recent years, the percentage of high-risk PCa has significantly increased, as well as the number of prostatectomies performed in patients with unfavorable morphologic features. However, the high-risk group criteria are not fully defined yet. According to various medical associations, a locally advanced or localized disease may have a high risk of progression. Study objective: to evaluate early and long-term results of treatment of patients with high-risk PCa depending on the high-risk group criteria. Materials and methods. The analysis includes results of radical surgical treatment of 832 patients with localized or locally advanced high-risk PCa treated in three medical institutions in St. Petersburg in the period from 2001 to 2019. Clinically high-risk group included patients with one of the following criteria: prostate specific antigen level >20 ng/ml, Gleason score >8, stage (cT); according to the last criterion two groups of patients were identified: HR-EAU (≥cT2c; n = 408) and HR-NCCN (≥cT3a; n = 282). Results. The average prostate specific antigen level was 21.09 and 26.63 ng/ml, respectively, in HR-EAU and HR-NCCN groups (p< 0.0001). The incidence of positive surgical margin, positive lymph nodes (pN+), five-year recurrence-free, cancer-specific, and overall survival did not differ significantly between the clinically high-risk groups. When evaluated according to the criteria obtained from pathomorphological examination of the removed prostate, the HR-NCCN group showed higher frequency of positive surgical margin (24.8 % vs. 19.2 %) and frequency of pN+ (22.4 % vs. 10.4 %). Analysis of long-term outcomes showed less favorable 5-year results in the HR-NCCN group (recurrence-free, cancerspecific, overall survival - 54.8, 87.0, 83.7 %) compared to the HR-EAU group (recurrence-free, cancer-specific, overall survival - 71.0, 92.1, 88.2 %) (p <0.02 for all). Conclusion. Differences in the high-risk group criteria by clinical indicators between associations do not affect early (frequency of positive surgical margin, pN+) and long-term (recurrence-free, cancer-specific, overall survival) outcomes. Pathomorphological indicators are less favorable when evaluated according to NCCN. According to our results, any of the proposed models can be used before radical prostatectomy to determine the prognosis of high-risk PCa patients. However, the NCCN morphological prognostic factors allow better prediction of outcomes and, in accordance with them, prescribe treatment that corresponds to the aggressiveness of the disease.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67765820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of clips and electrosurgical instruments in sealing of lymphatic vessels during pelvic lymph node dissection at the time of radical cystectomy","authors":"S. Kotov, A. O. Prostomolotov, A. Nemenov, A. Klimenko, I. S. Pavlov","doi":"10.17650/1726-9776-2021-17-2-93-102","DOIUrl":"https://doi.org/10.17650/1726-9776-2021-17-2-93-102","url":null,"abstract":"Background. Bladder cancer is very common and real problem in oncourology. The main treatment for muscle invasive bladder cancer is radical cystectomy (RC). RC with pelvic lymph node dissection (PLND) may be associated with an increased risk of developing lymphatic complications such as lymphedema, prolonged lymphorrhea, and the formation of lymphocele.Objective: to compare the efficiency of clips and surgical instruments for preventing the development of lymphatic complications during PLND at the time of RC.Materials and methods. From January 2016 to October 2020 at the N.I. Pirogov Russian National Research Medical University on the basis of N.I. Pirogov City Clinical Hospital No. 1 were performed 60 RC with PLND. All patients were divided into two groups. The 1st group included patients who underwent the sealing of lymphatic vessels using titanium/polymer clips (n = 30). In the 2nd group the sealing was performed using ultrasonic/bipolar instruments (n = 30). All operations were performed by one surgeon. The study used univariate and multivariate logistic regression analysis.Results. The overall percentage of lymphatic complications was 29 (48.3 %) out of 60 patients. Out of them 7 (11.7 %) patients developed symptomatic lymphocele, and 3 (5.0 %) developed asymptomatic lymphocele, prolonged lymphorrhea was observed in 17 (28.3 %) patients, lymphedema of the lower extremities or genitals in 2 (3.3 %). The percentage of lymphatic complications in the 1st group was 66.7 % (n = 20), and in the 2nd group - 30.0 % (n = 9) (p = 0.004). In multivariate analysis the statistical significance was (p = 0.014), a high odds ratio (6.83; 95 % confidence interval 1.48-31.49) was observed with sealing of lymphatic vessels with clips, while a low odds ratio (0.14; 95 % confidence interval 0.03-0.67) was found with electrosurgical instruments.Conclusion. The use of ultrasonic or bipolar electrosurgical instruments can be an effective method for preventing the development of lymphatic complications during PLND at the time of RC.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67766826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Renal cell carcinoma with metastases to the external genitalia. Literature review and case report","authors":"K. Menshikov, A. V. Sultanbaev, S. Musin, A. A. Izmaylov, R. R. Muginov, I. Menshikova, I. A. Sharifgaleev, D. Lipatov, N. Sultanbaeva","doi":"10.17650/1726-9776-2021-17-2-174-181","DOIUrl":"https://doi.org/10.17650/1726-9776-2021-17-2-174-181","url":null,"abstract":"Annually, up to 300 thousand new cases of kidney cancer and more than 134 thousand deaths associated with this disease are registered in the world. In the Russian Federation in 2019, 20,758 patients with a newly diagnosed renal cell carcinoma were registered; it should be noted that at the end of 2019, 177,755 patients with this diagnosis were registered. The issue of renal cell carcinoma metastasis seems to be quite relevant. The most common organs for metastatic renal cell carcinoma are lungs (up to 55 %), lymph nodes (up to 34 %), liver (up to 32 %), bones (up to 32 %), adrenal glands (up to 19 %), contralateral kidney (up to 11 %) and the brain (up to 5.7 %). The incidence of skin metastases in renal cell carcinoma ranges from 2.8 to 6.8 %, according to various authors.Our publication presents a case of treatment of a patient with a rare localization of renal cell carcinoma metastases in the external genital organs. The patient underwent palliative nephrectomy and vulvectomy. Taking into account the data on the prevalence of the disease, therapy with cabozantinib is carried out. Cabosantinib is an inhibitor of the tyrosine kinase domains of a number of growth factors, angiogenesis, abnormal bone remodeling, metastasis, and drug resistance.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67765861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maria Sklodowska-Curie, Pierre Curie","authors":"O. B. Karyakin","doi":"10.17650/1726-9776-2021-17-2-195-199","DOIUrl":"https://doi.org/10.17650/1726-9776-2021-17-2-195-199","url":null,"abstract":"On July 26, 1895, Pierre Curie and Maria Sklodowska were married.  On June 23, 1903, Maria presented her doctoral dissertation “Investigation of radioactive substances” at the Sorbonne, which described the results of hard work in previous years, including the isolation of new elements - polonium and radium. In the same 1903, Marie and Pierre Curie were awarded the Nobel Prize in Physics “in recognition of the exceptional services they rendered to science through the joint research of radiation phenomena discovered by Professor Henri Becquerel”. She became the first female - laureate and remained the only one until 1935, when her daughter Irene was awarded the Nobel Prize.  In 1911, Marie Curie received the Nobel Prize in Chemistry “for outstanding achievements in the development of chemistry: the discovery of the elements radium and polonium, the isolation of radium and the study of the nature and compounds of this remarkable element”. Marie Curie became the first and to date the only woman in the world -twice the Nobel Prize winner.  After many years, the proposal of Marie and Pierre Curie on the use of radium in medicine has been implemented at the present time. Studied and proved its effectiveness in the treatment of bone metastases of prostate cancer.  The merits of these scientists before the whole world can hardly be overestimated. Humanity gratefully keeps a good memory for great discoveries for the benefit of people.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67765879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Markers of bladder cancer: their role and prognostic significance (literature review)","authors":"L. I. Belyakova, A. N. Shevchenko, A. Sagakyants, E. Filatova","doi":"10.17650/17269776-2021-17-2-145-156","DOIUrl":"https://doi.org/10.17650/17269776-2021-17-2-145-156","url":null,"abstract":"This review article is devoted to the main problems of early diagnostic and prognosis of non-muscle-invasive bladder cancer, which accounts for 75 % of all newly detected cases of bladder cancer according to statistics. Chromosomal disorders that have been detected in urothelial cells can lead to the development of non-muscle-invasive bladder cancer. The review highlights the main problems of existing diagnostic systems for bladder cancer, their disadvantage and limitations of use in practice. Special attention is given to tumor stem cells, which are actively involved in the development of relapses of malignant neoplasms, and, also play an important role in the development of chemo - and radioresistance of tumor cells. Their significance in the diagnosis, detection of disease recurrence and the possibility of using the data obtained to adjustment therapeutic methods of treatment in oncology is one of the main tasks in cancer pathology.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1,"publicationDate":"2021-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67766262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FGFR3, TERT, ТР53 mutations and the FGFR3 gene expression in bladder cancer as prognostic markers","authors":"D. Mikhaylenko, S. A. Sergienko, E. Kuznetsova, I. N. Zaborsky, M. I. Martynov, O. Loran, G. Efremov, S. Y. Samoylova, B. Alekseev, V. Musatova, I. Bure, M. Nemtsova","doi":"10.17650/1726-9776-2021-17-1-89-100","DOIUrl":"https://doi.org/10.17650/1726-9776-2021-17-1-89-100","url":null,"abstract":"Background. Bladder cancer (BC) is a common urological cancer, 75 % of which are non-muscle invasive BC. After removal of the primary tumor, the adequate classification of malignancy and the defining of tumor progression risk remains an important issue, since it is associated with frequency of cystoscopy and choice of the BCG- or chemotherapy management.Objective: improve the algorithms of prognosis in intermediate-risk patients with non-muscle-invasive bladder cancer with the consideration of molecular characteristics of the primary tumor.Materials and methods. We studied 125 BC samples; mutations in the FGFR3, PIK3CA, TERT, and TP53 genes were determined by polymerase chain reaction and Sanger sequencing, as well as the expression of the FGFR3, EGFR, ERBB2, FOXA1, and GATA3 genes using realtime polymerase chain reaction.Results. Somatic mutations in the studied loci were detected in 65.6 % of the samples, five new mutations were identified. A decrease of the mutation frequency in the FGFR3 and TERT genes was shown, an increase — TP53 in order (Ta—T1/low G) > (T1/high G) > (>T2/any G). The largest area under the ROC curve (0.807 ± 0.092, р = 0.004) was demonstratedfor the prognostic classifier with the independent variables: mutation in FGFR3 and/or TERT; mutation TP53; overexpression of the FGFR3 gene. The FGFR3, TERT mutations and/or FGFR3 overexpression in the absence of TP53 mutation indicates minimally invasive primary tumor. On the contrary, harboring TP53 mutation indicate the features of muscle-invasive BC at the genetic level. Using this algorithm, we reclassified 21 of T1G3 BC cases as having characteristics associated with non-invasive tumor in 43 %, and invasive BC in 57 % of patients.Conclusion. The aforementioned prognostic model could be used as additional laboratory test in assessing the malignancy and progression risk of non-muscle invasive BC.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"17 1","pages":"89-100"},"PeriodicalIF":0.1,"publicationDate":"2021-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49633165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}